2023年8月14日,

IM大麻公司(納斯達克:IMCC) (CSE: IMCC)宣布其第二季度財務結果今天截至6月30日,2023年。所有發表在加拿大元。IM大麻的收入增長了4%,第二季度的1320萬美元和去年的同期為1270萬美元。淨損失持平[…]在其他新聞公司仍在虧損。以大麻為基礎的製藥公司MediPharm實驗室公司(TSX:實驗室)(OTCQX: MEDIF)報道,截至6月30日的第二季度收入上升,主要歸因於其最近收購VIVO大麻。的體內MediPharm翻了一倍以上的收入為960萬美元,同比增長120%和前一年的時期和64%的順序。公司的另一個裏程碑是一個產品的裝運到美國大規模的二期臨床試驗。這是與一個積極的毛利潤率連續第三個季度,公司2019年第四季度以來最高,徘徊在21%。MediPharm報道1470萬美元現金約300萬美元的債務和短期銷售前景在即將到來的季度現金生成能力。淨虧損總計270萬美元和898萬美元,去年同期根據提交給監管機構的文件。 In a statement , MediPharm Labs’ CEO David Pidduck expressed satisfaction with the second-quarter results, highlighting the smooth integration of VIVO. “We are excited to have new employees, new business units, new products and capabilities and new investors and stakeholders,” said Pidduck. The Canadian medical cannabis market has been a source of growth for MediPharm, it said, with revenues surging from $200,000 in prior year’s period to $3.8 million now. The boost was driven by the integration of VIVO’s medical branch, Canna Farms. Internationally, the company saw a 249% growth year-over-year, primarily from VIVO’s Australian business, Beacon Medical Australia. Beacon stands out as the third top-selling flower brand, with the company expecting similar success with new high margin products soon to launch. The company’s adjusted EBITDA was a loss $3.2 million, a 50% improvement from the same period in 2022. Additionally, the figure remained consistent sequentially, even after the VIVO incorporation, which had a historical adjusted EBITDA of negative $2 million per quarter. During the quarter, MediPharm entered into a supply agreement with a large generic pharmaceutical company in Brazil. With similar previous approvals in Brazil, product deliveries could commence by the first quarter of 2024, providing a boost to Brazilian revenue streams. On the regulatory front, MediPharm completed its first delivery of cannabis clinical trial material to a U.S. research partner in July 2023. The company also remains in close correspondence with the U.S. Food and Drug Administration (FDA) regarding its November 2022 on-site inspection of the Barrie facility in Canada. “This is the first U.S. FDA Audit of a purpose-built commercial cannabis facility in Canada,” the company said in the release. “We continued to make progress by growing our revenue base, improving gross margins, reducing expenses and reducing cash burn as we drive towards profitability,” CFO Greg Hunter added. “We have also demonstrated that we can quickly integrate and drive synergies through acquisitions.” Adam Jackson Adam Jackson writes about the cannabis industry for the Green Market Report. He previously covered the Missouri Statehouse for the Columbia Missourian and has written for the Missouri Independent. He most recently covered retail, restaurants and other consumer companies for Bloomberg Business News. You can find him on Twitter at @adam_sjackson and email him at adam.jackson@crain.com.